DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Gulf International Bank UK Ltd

Gulf International Bank UK Ltd lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,354 shares of the medical device company’s stock after selling 284 shares during the quarter. Gulf International Bank UK Ltd’s holdings in DexCom were worth $2,360,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of DXCM. Private Advisor Group LLC grew its position in shares of DexCom by 5.7% during the third quarter. Private Advisor Group LLC now owns 11,318 shares of the medical device company’s stock worth $759,000 after buying an additional 608 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of DexCom in the 3rd quarter worth about $930,000. abrdn plc raised its stake in shares of DexCom by 28.4% in the 3rd quarter. abrdn plc now owns 384,646 shares of the medical device company’s stock valued at $25,842,000 after purchasing an additional 85,174 shares in the last quarter. New York State Teachers Retirement System lifted its position in shares of DexCom by 1.6% during the third quarter. New York State Teachers Retirement System now owns 366,308 shares of the medical device company’s stock worth $24,557,000 after purchasing an additional 5,804 shares during the last quarter. Finally, AustralianSuper Pty Ltd grew its stake in DexCom by 54.8% in the third quarter. AustralianSuper Pty Ltd now owns 15,725 shares of the medical device company’s stock worth $1,054,000 after purchasing an additional 5,568 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is owned by company insiders.

DexCom Trading Up 0.6 %

NASDAQ:DXCM opened at $88.37 on Friday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The firm has a market capitalization of $34.53 billion, a P/E ratio of 61.80, a P/E/G ratio of 2.30 and a beta of 1.14. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The business has a 50 day simple moving average of $84.69 and a 200 day simple moving average of $76.67.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on DXCM. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Wells Fargo & Company boosted their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and boosted their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $99.06.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.